Merck & Co., Inc. (MRK) Advances Oncology Pipeline with Breakthrough FDA Designation for Ovarian Cancer Drug

Core Insights - Merck & Co., Inc. is identified as one of the most undervalued stocks in the Dow, recognized for its leadership in pharmaceuticals, vaccines, biologics, and animal health products [1] Group 1: Recent Developments - The FDA approved KEYTRUDA QLEX, a new subcutaneous injectable formulation of Keytruda, on September 19, 2025, which enhances patient convenience by reducing administration time from 30 minutes to 1-2 minutes [2] - In Europe, Merck received a positive opinion from the European Medicines Agency for ENFLONSIA (clesrovimab), a preventive for RSV in infants, which would be the first weight-independent option for this demographic if approved [3] Group 2: Financial Performance - Merck reported strong Q2 2025 results, with analysts highlighting its robust vaccine franchise, animal health segment, and innovative oncology treatments, including combination therapies with Keytruda [4] - The company is advancing novel drug candidates, such as raludotatug deruxtecan, which has received FDA Breakthrough Therapy Designation for treating platinum-resistant ovarian and related cancers [4]